Every Form 4 that TransDigm Group Incorporated (TDG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TDG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDG filings page.
TransDigm Group Inc. (TDG) Co-Chief Operating Officer Joel Reiss reported an insider transaction involving company common stock. On 11/17/2025, he exercised a stock option to acquire 3,900 shares of TransDigm common stock at an exercise price of $284.97 per share and, on the same date, reported a series of open-market sales of common stock at average prices generally between about $1,326.16 and $1,353.92 per share. Following these transactions, he reported beneficial ownership of 3,600 shares of common stock held directly and 43,100 stock options held directly.
TransDigm Group Inc. (TDG) director and President & CEO Michael J. Lisman reported multiple open‑market purchases of common stock on 11/14/2025 through the Michael Lisman Declaration of Trust dated January 31, 2023. The trust acquired 1,954 shares of TransDigm common stock in several transactions, including 600 shares at $1,334.13 and additional blocks at weighted average prices of $1,337.3825, $1,338.5578, $1,341.4904, $1,342.9335, and $1,344.7603 per share. After these transactions, Lisman is reported as beneficially owning 1,954 shares indirectly via the trust and 2,309 shares directly, with the direct holdings noted as previously omitted from an earlier report.
TransDigm Group (TDG) director W. Nicholas Howley, through the W. Nicholas Howley Family Trust, reported an option exercise and related stock sales. On 11/17/2025, the trust exercised a stock option for 2,736 shares of common stock at $50.92 per share, converting a derivative award into common shares. On the same date, the trust sold multiple small blocks of TransDigm common stock in open market transactions at weighted average prices generally between about $1,327 and $1,348 per share, as detailed in the footnotes. After these transactions, the trust held 21,547.513 shares of TransDigm common stock indirectly on behalf of the reporting person.
TransDigm Group (TDG) reported that director David Barr acquired 518 stock options on 11/04/2025 (transaction code A) with an exercise price of $1,291.97 per share. The options expire 11/04/2035 and vest 20% per year over five years beginning September 30, 2026, subject to achieving annual operating performance targets. Following the transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) filed a Form 4 for director Jane Cronin reporting a grant of stock options on 11/04/2025. The award covers 518 options with an exercise price of $1,291.97 per share.
The options vest 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. Following this transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) reported a Form 4 for a director, reflecting a grant of stock options for 518 shares on November 4, 2025 with an exercise price of $1,291.97 per share and an expiration date of November 4, 2035.
The options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets. Following the grant, the reporting person held 518 derivative securities directly. The derivative security is a stock option on TransDigm common stock.
TransDigm Group (TDG) director Sean Hennessy reported a grant of 518 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on 11/04/2035. Following the grant, Hennessy beneficially owns 518 derivative securities, held directly.
TransDigm Group (TDG) reported an insider equity grant. Director W. Nicholas Howley received 518 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options vest 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. Following the grant, 518 derivative securities were beneficially owned directly.
TransDigm Group (TDG) — Form 4: Director Gary McCullough reported a grant of stock options on 11/04/2025. The award covers 518 options to purchase common stock at an exercise price of $1,291.97 per share, expiring on 11/04/2035. The filing lists 518 derivative securities beneficially owned following the transaction, held direct.
Per the footnote, the options vest 20% per year over five years beginning September 30, 2026, and are subject to annual operating performance targets.
TransDigm Group (TDG): Director Peter Palmer reported an equity grant on Form 4. He acquired stock options covering 518 shares on Nov 4, 2025 with an exercise price of $1,291.97 per share and an expiration date of Nov 4, 2035.
The options vest at 20% per year over five years, beginning Sept 30, 2026, and are subject to the achievement of annual operating performance targets each year. Following the transaction, 518 derivative securities were beneficially owned on a direct basis.
TransDigm Group (TDG) filed a Form 4 showing a director stock option grant. On 11/04/2025, a reporting person serving as a Director received stock options covering 518 shares at an exercise price of $1,291.97 per share. The options were reported as acquired (Code A) and are held directly.
The options expire on 11/04/2035 and vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets in each year.
TransDigm Group (TDG) reported that director Robert Small acquired 518 stock options on November 4, 2025 (Transaction Code A) with an exercise price of $1,291.97 per share and an expiration date of November 4, 2035.
The options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets. Following the transaction, 518 derivative securities were beneficially owned, held directly.
TransDigm Group (TDG) reported an insider equity award. Director Kevin Stein acquired 518 stock options on 11/04/2025 with an exercise price of $1,291.97.
The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on 11/04/2035. Following the grant, 518 derivative securities were beneficially owned on a direct basis.
TransDigm Group (TDG) reported a Form 4 showing a grant of 26,450 stock options to a Co‑Chief Operating Officer at an exercise price of $1,291.97 on November 4, 2025.
The options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets, and expire on November 4, 2035. Following the transaction, 26,450 derivative securities were beneficially owned, held directly. Transaction code: A (award).
TransDigm Group (TDG) reported an insider equity award. Officer Armani Vadiee (GC, CCO, Secretary) received a grant of 17,100 stock options on 11/04/2025 at an exercise price of $1,291.97 per share. The options expire on 11/04/2035.
Per the grant terms, the options vest at 20% per year over five years beginning September 30, 2026, subject to the achievement of annual operating performance targets each year. Following the reported transaction, 17,100 derivative securities were beneficially owned, held direct.
TransDigm Group (TDG) reported a Form 4 for CFO Sarah Wynne showing a grant of 8,700 stock options on 11/04/2025 with an exercise price of $1,291.97 per share.
The options vest 50% in 2029 and 50% in 2030, subject to the achievement of annual operating performance targets, and expire on 11/04/2035. The filing lists direct ownership.
TransDigm Group (TDG) reported a Form 4 for Co‑Chief Operating Officer Joel Reiss, reflecting a grant of stock options for 9,700 shares at an exercise price of $1,291.97 on 11/04/2025.
The options expire on 11/04/2035 and are scheduled to vest 50% in 2029 and 50% in 2030, subject to achieving annual operating performance targets in each year. Following the grant, 9,700 derivative securities are beneficially owned on a direct basis.
TransDigm Group (TDG) disclosed a Form 4 showing its President & CEO, Michael Lisman, received stock option grants on 11/04/2025. Two awards were reported with an exercise price of $1,291.97 and an expiration of 11/04/2035 (Transaction Code: A). The first grant covers 75,696 options; the second covers 3,907 options. Both were acquired at $0 for the derivative security and are listed as Direct (D) ownership.
Vesting is performance-based: the 75,696 options vest 20% per year over five years beginning September 30, 2026, subject to annual operating performance targets. The 3,907 options vest 80% in 2026 and 20% in 2027, subject to similar targets.
TransDigm Group (TDG) reported an insider transaction by its Co‑Chief Operating Officer. On 11/03/2025, the officer exercised 290 stock options at $269.42 and on the same day sold 290 common shares at a weighted average price of $1,310 (within a range of $1,310.0000–$1,310.9999).
Following these transactions, the officer directly owns 1,055 common shares and holds 2,030 stock options outstanding.
TransDigm Group (TDG): insider transaction reported. On 10/27/2025, the Fortuna Trust dated June 1, 2018, affiliated with a company director, exercised 700 stock options at $105.88 and sold 700 common shares at an average $1,360. Following these transactions, the trust held 8,158 common shares indirectly. The option exercise related to a grant exercisable since 09/30/2018 and expiring 04/25/2028, with 72,800 derivative securities remaining indirectly held.
TransDigm Group (TDG): Co-Chief Operating Officer reported an option exercise and same-day sale on 10/27/2025. The filing shows an M-code exercise of 580 shares via stock options at $269.42 per share, followed by an S-code sale of 580 shares at a weighted average price of $1,354.76.
After these transactions, the reporting person directly owned 1,055 shares of common stock. The sale price reflects trades within the disclosed range of $1,354.7600–$1,355.7599. Derivative holdings listed following the transaction show 2,320 stock options remaining outstanding, with the exercised grant originally dated 09/30/2020 and expiring 11/10/2026.
TransDigm Group (TDG): insider transaction — Co‑Chief Operating Officer Joel Reiss exercised 3,000 stock options at $284.97 and, on the same day (10/20/2025), sold 3,000 common shares in multiple open‑market trades.
The reported sales were executed in tranches priced between $1,272.04 and $1,284.00, with several weighted‑average prices disclosed. Following these transactions, Mr. Reiss reported 3,600 common shares beneficially owned directly. He also reported 47,000 derivative securities (stock options) beneficially owned, with the exercised option series having an exercise price of $284.97, first exercisable on 09/30/2021 and expiring on 11/08/2027.
TransDigm Group (TDG): Director W. Nicholas Howley, through the W. Nicholas Howley Family Trust u/a/d 4/23/99, reported an option exercise and related share sales on 10/15/2025. The trust exercised stock options for 2,736 shares at $50.92 per share (exercise price adjusted for dividends declared since August 1, 2022) and executed multiple sales totaling 2,736 shares.
Sale prices were recorded at weighted averages across individual trades, with disclosed ranges from $1,291.6700 to $1,308.24. Following these transactions, the trust beneficially owns 21,547.513 shares of common stock indirectly. The filing also shows 1,881 derivative securities remaining beneficially owned indirectly after the reported transactions.
TransDigm (TDG) insider activity: Joel Reiss, listed as Co-Chief Operating Officer, reported transactions dated 09/22/2025. He exercised a stock option covering 3,000 shares at an exercise price of $284.97 and simultaneously sold 3,000 common shares in multiple trades at weighted average prices reported in ranges of approximately $1,270.01 to $1,279.40 per share.
After these transactions Reiss beneficially owned 3,600 shares of common stock and continued to hold 50,000 stock options exercisable through 11/08/2027. The Form 4 was signed by an attorney-in-fact on 09/24/2025 and includes weighted-average price explanations for the sales.
Amended Form 4 for TransDigm Group Inc. (TDG) shows that Robert J. Small, a director, filed an amendment correcting a prior filing and reporting a disposition of 5,625 shares. The earliest transaction date reported is 09/19/2025, and the amendment was filed on 09/22/2025. The filing states the prior Form 4 included an incorrect amount of common stock directly owned by the reporting person. Ownership following the reported transaction is listed as direct. No price per share or proceeds are disclosed in the submitted text.
TransDigm Group Inc. (TDG) director Michele Santana received 29 shares of common stock on 09/19/2025 as payment under the company's Director Share Plan. The filing states the shares were issued in lieu of a semi-annual director fee and were valued at $1,288.13. After the transaction Ms. Santana beneficially owned 741 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/22/2025 and indicates the issuance followed the plan's fair market value provisions.
Sean P. Hennessy, a director of TransDigm Group Inc. (TDG), reported a non-derivative transaction dated 09/19/2025 in which he acquired 36 shares of the issuer under the companys Director Share Plan in lieu of a semi-annual director fee. The form lists a price of $1,288.13 and shows 33,749.09 shares beneficially owned following the reported transaction. The filing explicitly states the receipt of stock was made in accordance with the Director Share Plan and valued at fair market value. The Form 4 was signed on 09/22/2025 by an attorney-in-fact.
Michael Graff, a director of TransDigm Group Inc. (TDG), reported the acquisition of 29 shares of TransDigm common stock on 09/19/2025 as payment in lieu of his semi-annual director fee under the companys Director Share Plan; the shares were valued at $1,288.13. After the transaction he directly beneficially owns 1,993 shares and indirectly beneficially owns 5,096 shares held by The 2012 Carol Ostrow GST Trust and 7,000 shares held by other trusts for his children (for which he is trustee), totaling 14,089 shares reported on this Form 4. The filing was submitted as a single-person Form 4 and signed by an attorney-in-fact on 09/22/2025. No derivative transactions were reported.
Jane M. Cronin, a director of TransDigm Group Incorporated (TDG), reported an acquisition of common stock on 09/19/2025. The Form 4 shows a transaction coded A (acquisition) for 29 shares and includes the figures $1,288.13 and 669.62 in the reporting line. The Explanation of Responses states these shares were received in lieu of payment of a semi-annual director fee under the company’s Director Share Plan and were valued based on fair market value.
The filing is signed by an attorney-in-fact on behalf of the reporting person and indicates the filing was made by one reporting person. No derivative transactions, amendments, or additional material events are disclosed in this Form 4.
David Barr, a director of TransDigm Group Inc. (TDG), reported a Form 4 disclosing a non‑derivative acquisition of company common stock on 09/19/2025. The filing shows an acquisition coded A for "36(1)" shares with a listed price of $1,288.13 and reports 32,138 shares beneficially owned following the transaction. The explanation states the shares were received in lieu of a semi‑annual director fee under the companys Director Share Plan. The form is signed by an attorney‑in‑fact on 09/22/2025.
Robert J. Small, a director of TransDigm Group Inc. (TDG), received equity on 09/19/2025 as director compensation under the Director Share Plan. The Form 4 reports receipt of common stock in lieu of a semi-annual director fee, and after the transaction the Reporting Person directly beneficially owned 15,625 shares. The filing lists additional indirect holdings: 441,814 shares held by Stockbridge Fund, L.P., 83,419 shares held by Stockbridge Partners LLC (managed account), and 60,246 shares held by certain family trusts. The report was signed by an attorney-in-fact on 09/22/2025 and discloses that the stock receipt was based on fair market value per the Director Share Plan.